RHJA
ANIK icon

Rice Hall James & Associates’s Anika Therapeutics ANIK Stock Holding History

Rice Hall James & Associates’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-47,987
Closed -$1.61M – 291
2018
Q4 		$1.61M Buy
47,987
+5,134
+12% +$185K 0.06% 201
2018
Q3 		$1.81M Buy
+42,853
New +$1.69M 0.06% 198
2014
Q1 		– Sell
-112,169
Closed -$4.28M – 300
2013
Q4 		$4.28M Sell
112,169
-2,800
-2% -$86.4K 0.31% 66
2013
Q3 		$2.75M Sell
114,969
-64,962
-36% -$1.46M 0.26% 125
2013
Q2 		$3.06M Buy
+179,931
New +$2.6M 0.3% 94

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Rice Hall James & Associates's ANIK Position: Q1 2019 in Review

Rice Hall James & Associates sold out of Anika Therapeutics (ANIK) in Q1 2019, closing a stake of 47,987 shares — an estimated $1.61M sold.

Rice Hall James & Associates first reported a position in ANIK in Q2 2013 and held it in 5 quarters. The position peaked at $4.28M in Q4 2013. 157 funds tracked by Wall St. Rank hold ANIK as of Q1 2019.

  • Rice Hall James & Associates reported no remaining Anika Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Rice Hall James & Associates sold 47,987 Anika Therapeutics shares in Q1 2019, an estimated $1.61M.
  • Rice Hall James & Associates first reported a position in Anika Therapeutics in Q2 2013 and held it in 5 quarters.
  • Rice Hall James & Associates's Anika Therapeutics position peaked at $4.28M in Q4 2013.
  • 157 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2019.

Based on Rice Hall James & Associates's 13F filing for Q1 2019, filed 1 May 2019.